In a pooled analysis carried out by Toshinari Takahashi et al., dotinurad (a novel selective urate reabsorption inhibitor) was found to reduce serum uric acid levels in hypertensive individuals suffering from asymptomatic hyperuricemia or gout. The percentage of people who attained a serum uric acid level of ≤6.0 mg/dL was greater than 80% in both 2- and 4-mg groups. 

This study was conducted to investigate dotinurad's efficacy (uric acid-lowering effect) in 222 participants in four clinical trials. Furthermore, the investigators examined dotinurad's long-term uric acid-lowering effect  in 154 participants. Table 1 denotes the percent alteration in the levels of serum uric acid and the percentage of people attaining a serum uric acid level of ≤6.0 with dotinurad usage at a dose of 2 mg and 4 mg.

Dotinurad's long-term uric acid-lowering effect displayed almost comparable results. As found, concomitant usage of angiotensin II receptor blockers or diuretics influenced dotinurad's efficacy at only 2 mg dose. Dotinurad showed an achievement rate of more than 80% for serum uric acid level of ≤6.0 mg/dL in both the analyses and appears to be clinically valuable to manage hyperuricemic states in people with hypertension.